Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.55 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.55 |
| ▸ | CA1 | P00915 | 5/20 | 0.49 |
| ▸ | CA2 | P00918 | 5/20 | 0.49 |
| ▸ | CA5A | P35218 | 5/20 | 0.49 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 0.49 |
| ▸ | FLT3 | P36888 | 4/20 | 0.47 |
| ▸ | ESRRG | P62508 | 1/20 | 0.46 |
| ▸ | MIF | P14174 | 1/20 | 0.46 |
| ▸ | NME4 | O00746 | 1/20 | 0.46 |
| ▸ | GCDH | Q92947 | 1/20 | 0.46 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.46 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23405482 | 0.91 | MAPT (0.83) | SNCAMAPTHSD17B1HSD17B2CA1 | |
| SCHEMBL23405495 | 0.90 | MAPT (0.82) | SNCAMAPTHSD17B1HSD17B2CA1 | |
| SCHEMBL23405476 | 0.90 | MAPT (0.81) | SNCAMAPTHSD17B1HSD17B2CA1 | |
| SCHEMBL23405494 | 0.90 | MAPT (0.81) | SNCAMAPTHSD17B1HSD17B2CA1 | |
| SCHEMBL23405479 | 0.88 | MAPT (0.78) | SNCAMAPTHSD17B1HSD17B2CA1 | |
| SCHEMBL23405496 | 0.88 | MAPT (0.78) | SNCAMAPTHSD17B1HSD17B2CA1 | |
| SCHEMBL23405489 | 0.88 | MAPT (0.78) | SNCAMAPTHSD17B1HSD17B2CA1 | |
| SCHEMBL23430997 | 0.87 | MAPT (0.77) | SNCAMAPTHSD17B1HSD17B2CA1 | |
| SCHEMBL23405505 | 0.84 | MAPT (0.72) | SNCAMAPTHSD17B1HSD17B2CA1 | |
| SCHEMBL23430953 | 0.84 | MAPT (0.72) | SNCAMAPTHSD17B1HSD17B2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180002298-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PROTAMED INC (US) | 2018-01-04 | — | — | US | disclosed |
| US-20170022174-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PROTAMED INC (US) | 2017-01-26 | — | — | US | disclosed |
| US-20170022174-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PROTAMED INC (US) | 2017-01-26 | — | — | US | disclosed |
| US-9334251-B2 | Compounds for the treatment of neurodegenerative diseases | PROTAMED, INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-9334251-B2 | Compounds for the treatment of neurodegenerative diseases | PROTAMED, INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-20150274681-A1 | Compounds for the treatment of Neurodegenerative Diseases | PROTEOTECH INC. (US) | 2015-10-01 | — | — | US | disclosed |
| US-20150274681-A1 | Compounds for the treatment of Neurodegenerative Diseases | PROTEOTECH INC. (US) | 2015-10-01 | — | — | US | disclosed |
| US-9085549-B2 | Compounds for the treatment of neurodegenerative diseases | PROTEOTECH INC (US) | 2015-07-21 | — | — | US | disclosed |
| US-9085549-B2 | Compounds for the treatment of neurodegenerative diseases | PROTEOTECH INC (US) | 2015-07-21 | — | — | US | disclosed |
| US-20150011604-A1 | Compounds for the treatment of neurodegenerative diseases | PROTEOTECH INC. (US) | 2015-01-08 | — | — | US | disclosed |
| US-20150011604-A1 | Compounds for the treatment of neurodegenerative diseases | PROTEOTECH INC. (US) | 2015-01-08 | — | — | US | disclosed |
| US-8865754-B2 | Compounds for the treatment of neurodegenerative diseases | PROTEOTECH INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-8865754-B2 | Compounds for the treatment of neurodegenerative diseases | PROTEOTECH INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-20120251448-A1 | Compounds for Use in the Detection of Neurodegenerative Diseases | AVID RADIOPHARMACEUTICALS, INC. | 2012-10-04 | — | — | US | disclosed |
| US-20120251448-A1 | Compounds for Use in the Detection of Neurodegenerative Diseases | AVID RADIOPHARMACEUTICALS, INC. | 2012-10-04 | — | — | US | disclosed |
| WO-2012118935-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PROTEOTECH INC (US) | 2012-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274681-A1 | Compounds for the treatment of Neurodegenerative Diseases | PSEN1, PSEN2, GRN | SNCA 18/4885MAPT 4/4885HSD17B1 1374/4885 |
| US-20180002298-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PSEN1, PSEN2, GRN | SNCA 18/4885MAPT 4/4885HSD17B1 1374/4885 |
| US-20150011604-A1 | Compounds for the treatment of neurodegenerative diseases | SNCA, MAPT, PARK7 | SNCA 1/4885MAPT 2/4885HSD17B1 3806/4885 |
| US-20120251448-A1 | Compounds for Use in the Detection of Neurodegenerative Diseases | SNCA, PARK7, NLN | SNCA 1/4885MAPT 15/4885HSD17B1 4489/4885 |
| US-20170022174-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PSEN1, PSEN2, GRN | SNCA 18/4885MAPT 4/4885HSD17B1 1374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.